These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 1665128)

  • 1. Antiplatelet effects of endothelium-derived relaxing factor and nitric oxide donors.
    Bassenge E
    Eur Heart J; 1991 Nov; 12 Suppl E():12-5. PubMed ID: 1665128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of platelet activation by endothelium-derived relaxing factor EDRF/NO and NO releasing dilator substances].
    Bassenge E
    Z Kardiol; 1991; 80 Suppl 5():17-21. PubMed ID: 1776330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibition of thrombocyte aggregation and adhesion by endothelium-derived relaxant factor (EDRF) and their pathophysiologic significance].
    Bassenge E; Busse R; Pohl U
    Z Kardiol; 1989; 78 Suppl 6():54-8. PubMed ID: 2515672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LY 83583 (6-anilino-5,8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation.
    Mülsch A; Lückhoff A; Pohl U; Busse R; Bassenge E
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):119-25. PubMed ID: 2552329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nitric oxide: the endogenous nitrate in the cardiovascular system].
    Tschudi MR; Lüscher TF
    Herz; 1996 Jun; 21 Suppl 1():50-60. PubMed ID: 8767925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelium-derived relaxing factor (EDRF): a defence mechanism against platelet aggregation and vasospasm in human coronary arteries.
    Förstermann U; Mügge A; Alheid U; Bode SM; Frölich JC
    Eur Heart J; 1989 Nov; 10 Suppl F():36-43. PubMed ID: 2620689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary vasomotor responses: role of endothelium and nitrovasodilators.
    Bassenge E
    Cardiovasc Drugs Ther; 1994 Aug; 8(4):601-10. PubMed ID: 7531489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of platelet cyclic GMP but not cyclic AMP suppression in leukocyte-dependent platelet adhesion to endothelial cells induced by platelet-activating factor in vitro.
    Hirafuji M; Nezu A; Shinoda H; Minami M
    Br J Pharmacol; 1996 Jan; 117(2):299-304. PubMed ID: 8789382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous endothelium-derived relaxing factor inhibits platelet adhesion under whole blood flow conditions ex vivo.
    Jen CJ; Chen CT; Chen H
    Chin J Physiol; 1995; 38(3):147-51. PubMed ID: 8846723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial cGMP does not regulate basal release of endothelium-derived relaxing factor in culture.
    Marczin N; Ryan US; Catravas JD
    Am J Physiol; 1992 Jul; 263(1 Pt 1):L113-21. PubMed ID: 1379001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.
    Stamler JS; Osborne JA; Jaraki O; Rabbani LE; Mullins M; Singel D; Loscalzo J
    J Clin Invest; 1993 Jan; 91(1):308-18. PubMed ID: 8380812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition.
    Dangel O; Mergia E; Karlisch K; Groneberg D; Koesling D; Friebe A
    J Thromb Haemost; 2010 Jun; 8(6):1343-52. PubMed ID: 20149081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelium-derived relaxant factor inhibits platelet activation.
    Busse R; Lückhoff A; Bassenge E
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):566-71. PubMed ID: 2830546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous measurement of endothelium-derived relaxing factor by bioassay and guanylate cyclase stimulation.
    Kondo K; Mitchell JA; de Nucci G; Vane JR
    Br J Pharmacol; 1989 Oct; 98(2):630-6. PubMed ID: 2573403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators.
    Salvemini D; Currie MG; Mollace V
    J Clin Invest; 1996 Jun; 97(11):2562-8. PubMed ID: 8647949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of nitric oxide/cGMP system in platelet function].
    Inoue N
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():500-4. PubMed ID: 15506436
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors.
    Salvemini D; Radziszewski W; Korbut R; Vane J
    Br J Pharmacol; 1990 Dec; 101(4):991-5. PubMed ID: 1707709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed.
    Pohl U; Busse R
    Circ Res; 1989 Dec; 65(6):1798-803. PubMed ID: 2555082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Endothelium-derived relaxing factor(s): endogenous nitrates in the circulation?].
    Lüscher TF; Yang Z; Diederich D; Schneider K; von Segesser L; Siebenmann R; Stulz P; Bühler FR
    Schweiz Med Wochenschr; 1988 Nov; 118(46):1724-9. PubMed ID: 3062771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the pharmacological actions of nitrovasodilators by methylene blue and pyocyanin.
    Gryglewski RJ; Zembowicz A; Salvemini D; Taylor GW; Vane JR
    Br J Pharmacol; 1992 Aug; 106(4):838-45. PubMed ID: 1327388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.